VolitionRx Limited (NYSE AMERICAN: VNRX) is proud to announce the launch of its revolutionary Nu.Q® Vet Cancer Test, now available in the United States through IDEXX Laboratories, Inc.’s extensive reference laboratory network. The Nu.Q® Vet Cancer Test is a groundbreaking epigenetics-based solution that has the potential to revolutionize the diagnosis and treatment of pet cancer.
Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, is thrilled to announce the global launch of IDEXX Nu.Q® Canine Cancer Screen — a revolutionary, cost-effective, and easy-to-use blood test for screening older or ‘at risk’ dogs. IDEXX is a global leader in pet healthcare innovation, and is proud to introduce this breakthrough product to the market.
Our Nucleosomics™ technology makes it easy for veterinarians to incorporate it into annual wellness visits, allowing for earlier detection and treatment of cancer and ultimately improving the health of pets and pet owners. By integrating this technology into regular care, veterinarians can better inform their clinical decisions to provide a higher standard of care.
IDEXX is making a major move this week with the launch of their Nu.Q® Canine Cancer Screen in the U.S., giving customers worldwide access to their innovative Nu.Q® technology. Our supply agreement¹ opens up an abundance of opportunities in the companion animal healthcare sector, allowing IDEXX to capitalize on a promising future.
Volition is revolutionizing the world of diagnostics with their simple, easy-to-use, cost-effective blood tests. These tests have the potential to quickly diagnose and monitor a range of life-altering diseases, including cancer, in both humans and animals. The future of healthcare is here, as Volition brings us one step closer to a world without the fear of cancer and other life-altering diseases.
Note to editors:
A clinical study conducted by Volition and Professor Wilson-Robles and their team at Texas A&M University has revealed impressive results for the company’s Nu.Q® Vet Cancer Test. Published in August 2022, the study showed that the test detected 76% of systemic cancers (including lymphoma, hemangiosarcoma, and histiocytic sarcoma) with an impressive 97% specificity compared to a control. As a result, Volition has signed a global supply agreement for the test.
About the U.S. market segment
- The Veterinary Cancer Society estimates that an alarming one in four dogs will develop cancer in their lifetime, with almost half of those over the age of 10 being affected.
- A recent Pet Owner Survey conducted by the Human Animal Bond Research Institute (HABRI) Foundation found that an overwhelming 95% of pet owners view their furry family members as just that – family.
- Despite this, statistics from IDEXX show that only around half of dogs have preventative care visits each year, leading to an estimated six million new cancer diagnoses in dogs throughout the U.S. alone.
- Furthermore, IDEXX’s team of global pathologists reviews over one million suspected cancer case submissions in companion animals annually, and expected a 9% growth in wellness visits in 2021, with a similar trend forecasted in 2022.
Volition is a pioneering epigenetics company that uses its advanced Nucleosomics™ platform to provide simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases in humans and other animals. Through early diagnosis and monitoring, Volition enables patients to not only extend their lives, but also to improve their quality of life. Nucleosomics™ is the science behind these tests, which use the presence of nucleosomes in the bloodstream or other bodily fluid to indicate the presence of disease.
Volition, a research and development company, has established a global presence with its innovation laboratory and office in the U.S., as well as offices in London, Belgium, and Singapore. With its global reach, the company is committed to delivering cutting-edge solutions to its clients.
The information found at Volition’s website address is not part of this document, but simply referred to as an inactive reference. Therefore, it should not be taken into consideration when reading this document.
Safe Harbor Statement
Volition’s future success could depend on its ability to develop and successfully commercialize its blood-based diagnostic, prognostic and disease monitoring tests. These tests have the potential to provide early detection of cancer and other diseases, as well as serve as diagnostic, prognostic or disease monitoring tools. However, Volition could face challenges in the form of fierce competition and rapid technological change, as well as the potential for failure to obtain necessary regulatory clearances or approvals to distribute and market its products. Moreover, the marketplace may not accept its products, thereby preventing Volition from executing its plan of operations. It is therefore essential for Volition to be prepared for all these risks and uncertainties in order to realize its estimated market opportunity and the potential benefits under the supply agreement with IDEXX.
VolitionRx Limited and its subsidiaries have developed two advanced technologies – Nucleosomics™ and Nu.Q® – both of which are recognizable by their respective logos. These are trademarks and/or service marks that demonstrate the cutting-edge research and development of this innovative company. All other trademarks, service marks, and trade names referred to in this press release are the property of their respective owners.